Brief: Minerva Neurosciences Submits New Drug Application To FDA For Roluperidone For Treatment Of Negative Symptoms In Patients With Schizophrenia
22/08/2022 13:06
Aug 22 (Reuters) - Minerva Neurosciences Inc NERV.O :
* MINERVA NEUROSCIENCES SUBMITS NEW DRUG APPLICATION TO FDA
FOR
ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN PATIENTS
WITH SCHIZOPHRENIA
Source text for Eikon: ID:nGNE4VyC9r
Further company coverage: NERV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Minerva Neurosciences
See all newsU.S. RESEARCH ROUNDUP-Cisco, Fox Corp, Target
Brief: Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates
Brief: Minerva Neurosciences - To Offer And Sell Up To $75 Million In Common Stock Through Leerink Partners
Brief: Minerva Announces Leadership Transition
Minerva Neurosciences Q4 net loss widens on non-cash financing charges